Editas Medicine Company Insiders
| EDIT Stock | USD 2.76 0.03 1.10% |
Editas Medicine's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Editas Medicine suggests that vertually all insiders are panicking. Editas Medicine employs about 246 people. The company is managed by 23 executives with a total tenure of roughly 7 years, averaging almost 0.0 years of service per executive, having 10.7 employees per reported executive.
| James Mullen Chairman Chairman of the Board |
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
| 2025-06-03 | Linda Burkly | Disposed 726 @ 1.72 | View | ||
| 2024-12-03 | Gilmore Neil O'neill | Disposed 1618 @ 2.08 | View | ||
| 2024-09-04 | Gilmore Neil O'neill | Disposed 1555 @ 3.42 | View | ||
| 2024-07-25 | Linda Burkly | Disposed 11886 @ 5.42 | View |
Monitoring Editas Medicine's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. Editas Medicine's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Editas Medicine's future performance. Based on our forecasts, it is anticipated that Editas will maintain a workforce of slightly above 250 employees by August 2025.Editas Medicine Management Team Effectiveness
The company has return on total asset (ROA) of (0.368) % which means that it has lost $0.368 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4082) %, meaning that it created substantial loss on money invested by shareholders. Editas Medicine's management efficiency ratios could be used to measure how well Editas Medicine manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.73 in 2025. Return On Capital Employed is likely to drop to -0.95 in 2025. Liabilities And Stockholders Equity is likely to gain to about 394.2 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 44.6 M in 2025.Common Stock Shares Outstanding is likely to drop to about 54.2 M in 2025. Net Loss is likely to gain to about (188.5 M) in 2025
Editas Medicine Workforce Comparison
Editas Medicine is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 9,424. Editas Medicine holds roughly 246 in number of employees claiming about 2.61% of equities under Health Care industry.
Editas Medicine Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Editas Medicine insiders, such as employees or executives, is commonly permitted as long as it does not rely on Editas Medicine's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Editas Medicine insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-06-01 | 0.3333 | 1 | 3 | 34,672 | 16,364 |
| 2025-03-01 | 2.0 | 6 | 3 | 1,693,200 | 23,632 |
| 2024-06-01 | 3.0 | 9 | 3 | 245,000 | 35,039 |
| 2024-03-01 | 7.0 | 14 | 2 | 1,191,361 | 98,151 |
| 2023-09-01 | 0.5 | 2 | 4 | 180,667 | 5,263 |
| 2023-06-01 | 2.0 | 10 | 5 | 458,700 | 8,343 |
| 2023-03-01 | 1.1429 | 8 | 7 | 464,700 | 12,767 |
| 2022-09-01 | 0.3333 | 1 | 3 | 58,372 | 586.00 |
| 2022-06-01 | 3.2 | 16 | 5 | 1,617,187 | 9,350 |
| 2022-03-01 | 1.2 | 6 | 5 | 484,511 | 21,468 |
| 2021-12-01 | 1.5 | 6 | 4 | 82,479 | 15,660 |
| 2021-09-01 | 0.3333 | 3 | 9 | 52,714 | 226,177 |
| 2021-06-01 | 3.0 | 9 | 3 | 316,598 | 5,000 |
| 2021-03-01 | 2.5 | 5 | 2 | 269,937 | 2,830 |
| 2020-12-01 | 0.5 | 6 | 12 | 203,076 | 83,228 |
| 2020-09-01 | 0.2857 | 2 | 7 | 20,000 | 45,214 |
| 2020-06-01 | 5.0 | 5 | 1 | 57,690 | 151.00 |
| 2020-03-01 | 1.75 | 7 | 4 | 348,501 | 24,148 |
| 2019-12-01 | 2.0 | 2 | 1 | 175,000 | 0.00 |
| 2019-09-01 | 5.0 | 5 | 1 | 786,566 | 5,193 |
| 2019-03-01 | 1.0 | 15 | 15 | 216,903 | 65,790 |
| 2018-12-01 | 0.4286 | 12 | 28 | 66,644 | 111,852 |
| 2018-09-01 | 0.4074 | 11 | 27 | 46,000 | 132,666 |
| 2018-06-01 | 0.52 | 13 | 25 | 95,314 | 488,453 |
| 2018-03-01 | 0.3438 | 11 | 32 | 587,652 | 180,133 |
| 2017-12-01 | 0.1765 | 3 | 17 | 14,649 | 74,297 |
| 2017-09-01 | 0.2 | 1 | 5 | 1,686 | 33,332 |
| 2017-06-01 | 4.5 | 9 | 2 | 131,304 | 1,000,000 |
| 2017-03-01 | 0.7778 | 7 | 9 | 474,500 | 50,000 |
| 2016-12-01 | 0.0526 | 1 | 19 | 225,000 | 718,058 |
| 2016-09-01 | 0.3636 | 4 | 11 | 250,561 | 3,308,161 |
| 2016-03-01 | 0.434 | 23 | 53 | 32,279,313 | 78,507,074 |
Editas Medicine Notable Stakeholders
An Editas Medicine stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Editas Medicine often face trade-offs trying to please all of them. Editas Medicine's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Editas Medicine's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Pr Church | CoFounder Member | Profile | |
| Gilmore MD | CEO President | Profile | |
| Gilmore ONeill | CEO President | Profile | |
| James Mullen | Chairman of the Board | Profile | |
| CPA CFA | CFO VP | Profile | |
| Damien JD | General VP | Profile | |
| Bruce Eaton | Exec Officer | Profile | |
| Cristi Barnett | Corporate Relations | Profile | |
| Charlene JD | Executive Counsel | Profile | |
| Michelle Robertson | Principal CFO | Profile | |
| David Liu | CoFounder Member | Profile | |
| Caren Deardorf | Executive Officer | Profile | |
| Harry III | VP Operations | Profile | |
| Amy Parison | Senior Finance | Profile | |
| Mark Shearman | Ex Officer | Profile | |
| Feng Zhang | CoFounder Member | Profile | |
| Baisong MD | Executive Officer | Profile | |
| Linea Aspesi | Executive Officer | Profile | |
| Brieana Buckley | Senior Leadership | Profile | |
| Linda Burkly | Executive Officer | Profile | |
| George Church | CoFounder Member | Profile | |
| Gregory Whitehead | Executive Officer | Profile | |
| Frank Panaccio | Senior Development | Profile |
About Editas Medicine Management Performance
The success or failure of an entity such as Editas Medicine often depends on how effective the management is. Editas Medicine management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Editas management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Editas management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.69) | (0.73) | |
| Return On Capital Employed | (0.90) | (0.95) | |
| Return On Assets | (0.69) | (0.73) | |
| Return On Equity | (1.77) | (1.68) |
Please note, the imprecision that can be found in Editas Medicine's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Editas Medicine. Check Editas Medicine's Beneish M Score to see the likelihood of Editas Medicine's management manipulating its earnings.
Editas Medicine Workforce Analysis
Traditionally, organizations such as Editas Medicine use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Editas Medicine within its industry.Editas Medicine Manpower Efficiency
Return on Editas Medicine Manpower
| Revenue Per Employee | 131.4K | |
| Revenue Per Executive | 1.4M | |
| Net Loss Per Employee | 963.8K | |
| Net Loss Per Executive | 10.3M | |
| Working Capital Per Employee | 862.2K | |
| Working Capital Per Executive | 9.2M |
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.